Alteogen

Alteogen Intangible Assets

The Intangible Assets of Alteogen (196170.KQ) as of Nov 4, 2026 is 112.03 B KRW. In the previous year, Intangible Assets was 89.22 B KRW — a change of 25.56% (higher).

Intangible Assets

112.03 BKRW

YoY

25.56%

Last updated:

Intangible Assets of Alteogen is 2024 112.03 B KRW. Intangible Assets of Alteogen was 2023 89.22 B KRW. It decreases by 25.56% higher compared to the previous year.

The Alteogen Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2017
488.00 M KRW
Jan 1, 2018
508.00 M KRW
Jan 1, 2019
631.00 M KRW
Jan 1, 2020
907.00 M KRW
Jan 1, 2021
11.24 B KRW
Jan 1, 2022
47.19 B KRW
Jan 1, 2023
89.22 B KRW
Jan 1, 2024
112.03 B KRW
The Alteogen Intangible Assets history
YEARIntangible AssetsYoY
112.03 BKRW+25.56%
89.22 BKRW+89.07%
47.19 BKRW+319.96%
11.24 BKRW+1,138.83%
907.00 MKRW+43.74%
631.00 MKRW+24.21%
508.00 MKRW+4.10%
488.00 MKRW-75.54%
2.00 BKRW+1,002.21%
181.00 MKRW+86.60%
97.00 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alteogen Stock analysis

What does Alteogen do? Alteogen, Inc. generates revenue through its biobetter business segment, developing protein pharmaceuticals and cancer therapies, and its bio similar business segment, focusing on bio similar and animal medicines. The company sells growth hormone, herceptin, humira, antibodies, and other products primarily to healthcare providers and pharmaceutical distributors. Its biobetter segment targets oncology and protein-based treatments, while the bio similar segment serves both human and animal health markets with cost-effective alternatives to branded drugs. The firm's product portfolio includes growth hormone, herceptin, and humira, which are key revenue drivers in the biopharmaceutical sector. Herceptin and humira are well-established anticancer drugs, while growth hormone addresses endocrine disorders. The company's bio similar segment offers affordable versions of these therapies, appealing to budget-conscious healthcare systems and veterinary markets. Sales are concentrated in the human and animal medicine sectors, leveraging its dual focus on biobetter and bio similar products. Alteogen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alteogen stock

Intangible Assets of Alteogen is 112.03 B KRW in 2024.

Intangible Assets of Alteogen changed from 89.22 B KRW to 112.03 B KRW, representing a 25.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Alteogen since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Alteogen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Alteogen

All Key Metrics — Alteogen